We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

FUM Futura Medical Plc

-0.25 (-0.83%)
Last Updated: 16:05:08
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Futura Medical Plc LSE:FUM London Ordinary Share GB0033278473 ORD 0.2P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.25 -0.83% 29.70 119,257 16:05:08
Bid Price Offer Price High Price Low Price Open Price
29.70 30.20 30.00 29.20 29.20
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations -5.85M -0.0194 -15.46 90.21M
Last Trade Time Trade Type Trade Size Trade Price Currency
16:05:15 O 10,000 30.0495 GBX

Futura Medical (FUM) Latest News

Futura Medical (FUM) Discussions and Chat

Futura Medical Forums and Chat

Date Time Title Posts
29/11/202309:56FUTURA a winner for 201519,999
31/10/202315:48fum value1
02/7/202309:15Quiet on here 34
12/6/202316:18FUTURA - FDA Approval Due in 20234
02/5/202316:29avoid fum share prophet4

Add a New Thread

Futura Medical (FUM) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type

Futura Medical (FUM) Top Chat Posts

Top Posts
Posted at 29/11/2023 08:20 by Futura Medical Daily Update
Futura Medical Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker FUM. The last closing price for Futura Medical was 29.95p.
Futura Medical currently has 300,712,293 shares in issue. The market capitalisation of Futura Medical is £90,213,688.
Futura Medical has a price to earnings ratio (PE ratio) of -15.46.
This morning FUM shares opened at 29.20p
Posted at 13/10/2023 17:06 by mdi
The first RNS regarding the Co High Chinese collaboration was 4/3/2021. The shares traded through 36p on 19/3/2021 on still unexplained very high volumes of over 36m shares trading on that day alone in March 2021. So the share price is back to where it was in March 2021 and anyone who bought in the market above the current share price of 36p over the last two and half years has lost money on those shares. The Co High exercising their warrants RNS was 1/4/2021 at 22p and the conversion of the Chinese collaboration convertible loan notes into 7.5m FUM shares at 20p was 15/4/2023. So Co High can keep selling those 20p shares into the market. Just like the Directors and employees who recently got 20p options can sell them all the way back down to 20p and still be in the money. With the small retail investors having to average down and be left sitting on more losses. While Co High and FUM Directors/employees continue to be able to sell out their millions of 20p shares making money at their expense until Haleon makes its announcement in ‘due course’ on the ‘ongoing regulatory development’ requirement for USA. Unlike with what happened with Co High and the exact reasons for why Eroxon failed to progress in China. Haleon is a public company so the detail and outcome of any ‘pivotal study’ ie double blind placebo controlled on Eroxon will eventually be made public.

‘Haleon is responsible for the future launch and ongoing regulatory, development, marketing, and commercialization of MED3000 in the USA. Further details will be disclosed in due course’
Posted at 13/10/2023 16:42 by martinelwick
The first part of this post has been lifted from my post on LSE. I immediately posted a correction. The share price was in fact 14.75. So if you had bought the you would have doubled your money!Liar Booth has resurfaced: beware he lost everything and is a sad bitter individual
Posted at 13/10/2023 16:09 by mdi
If you go back to the RNS dated 4/3/2021. Guess what the share price was around that day. 36p. So FUM are back to the share price obtained two and a half years ago. Co High got just under 9m shares for 20p but since then there was some unexplained collapse of this Chinese agreement with FUM. Many now saying its High Co who has been selling their remaining shareholding. Did the Chinese require the same ‘pivotal study’ as required by the FTC ie a pivotal double blind placebo controlled?

‘This is expected to include a pivotal study in order to gain OTC regulatory approval within China’

Is that why Co High are selling out before it’s announced about the Haleon study that also is now required?

‘China and South East Asia - Termination of commercial agreement

In March 2021 Futura announced a Joint Collaboration with Co-High for the regulatory development, approval and commercialisation of MED3000 in South East Asia. Unfortunately, this collaboration has not progressed as Futura had hoped’
Posted at 07/10/2023 10:44 by broomrigg
LOL.....thebutler's hot tip OSB, "a steal" at 500p, closed the week below 300p and there looks like very little support or confidence over there. The only thing supporting the price (slowing the collapse) is the company's own share buy-backs and how long can they keep that up for? The shares have almost halved in just a few weeks. Clearly better to have your money in FUM.
Posted at 05/9/2023 14:00 by broomrigg
You are right Rodders but I'm sure FUM will have plenty to say about sales on interims day in (less than) 2 weeks. Amazon sales, which grew steadily from an initial 2k+ per month to peak at 7k+ per month before dropping back to 3k+ are now consistently back up at 6k+ per month which suggests to me we are getting repeat orders, confirming what the CEO said in the recent Liberum interview. Figs in a years time and beyond will also be affected by FUM rolling-out into other markets and the initial interest that causes. It's a good thing, not negative.
Posted at 22/7/2023 14:54 by beanol
LBO1Thanks for this and your previous associated post. There are some helpful cautionary points in both. Couple of points I'm not a ramper. I came across this share early year and invested £5k, sold at a loss. Then invested again a larger amount. I am £3k up. I use this BB to see updated news and do my own research. And of course I like sharing views and challenging/confirming my own views and hypotheses. I wouldn't see this as being controversial. I have (some) relevant professional experience at a senior level and a few relevant contacts in the industry (although none with direct access). Your point about the history of FUM and deals that have not fulfilled their potential are difficult to argue against. If that's what happened I can understand that anybody who's experienced this would want to warn other investors. On the De Novo issue yes ...BUT the 3 shares I have invested in which achieved this status including GWP Pharma all went on to do really well. It IS an indication of FDA recognition of certain criteria. In terms of Haleon, I spoke to the wife of a close friend who works for them yesterday in a not commercial area. . She didn't say anything confidential but did say that the deal had generated a bit of a buzz inside the company and much mirth. In one of the internal comments the company confirmed that it had verified the product as being safe to use but would not be giving out free samples....I will be holding for the duration now ie until as you predict the product fails or in the unlikely event it succeeds. It remains odd to me that the share price has not improved substantially given such stonking good recent news.
Posted at 17/7/2023 19:34 by halfpenny
Be Patient as FuM is going all the way UP with further licenses being signed in a billion pound market.

I suspect FUM will be bought out at 125p as demand is UP for a great product.

Future is bright as FUM rise all the way UP!
Posted at 17/7/2023 09:12 by bg23
I will admit that if you'd asked me 6 months ago what the share price would be if the company had gained FDA approval for its product, a US marketing partner, european launch, etc, I'd have been thinking well north of 60p.

That said, all the ducks are lining up in a row, we're likely to have news on a US launch by year end alongside +£5m of sales from the soft european launch with the expectation of considerable 2024 and beyond sales revenue growth.

Upfront payments and warrant exercise remove the need for any cash raise. Further development and marketing costs being incurred by partners, stage payments and royalties flowing back to FUM.

I'm surprised that we are still at a valuation of only £170m, but think that just highlights the hidden value based on the progress of the last year.

So what if Lombard top slice their holding on a rising price, they've supported the company, provided capital and as a cornerstone investor, a supportive entity the company has been able to plan with. Different Investors will want involvement now that the approvals and partnerships are in the bag and as market cap increases, FUM will appear on a wider range of potential investors.

no one has mentioned the CEO's comment about imminent approval in Saudi and subsequent launch, but its a further ratification of the product and progress made.

Looking forward to seeing the US and broader European launch with resultant take-up of the product. the shareprice will look after itself.
Posted at 16/7/2023 14:47 by broomrigg
Thanks for posting that link to the BUY recommendation in today's Times BEANOL. NICE ONE. Here is the article in full peeps ........

Futura is looking for rapid growth

Lucy Tobin
Sunday July 16 2023, 12.01am, The Sunday Times

Futura Medical is an Aim-listed pharmaceuticals tiddler, with only 14 staff and directors, which sells a single, brand-new gel. It works out of a small Surrey University science park, and its share price has surged by 84 per cent since last year. So it’s not the obvious contender for a share tip.

However, Futura has made a new product that works, and it is only just starting to shout about it. The company’s Eroxon gel is the first erectile dysfunction product approved to go on sale without a prescription. It is already available at Boots and online via the likes of Amazon, and it is the first new ED treatment for two decades. Clinical trials showed Eroxon successfully pumped up 65 per cent of users. Given the scale of the stigma-ridden, $3 billion (£2.3 billion) global market for men suffering a lack of erections — it is forecast to surpass $6 billion by 2032 — Futura looks appealing.

Rival treatments, such as Viagra and Cialis, both need a prescription and take longer to work: the Eroxon gel acts in ten minutes; it’s half an hour with rivals.

Futura has also minimised risk by outsourcing all it can: it does the science, but then, said chief executive James Barder, looks for “commercial partners to do the rest” — the marketing and distribution. “We’ve done so in the UK, Europe, and seven countries in the Middle East. Saudi [Arabia’s] approval is expected in September — that’s the biggest erectile dysfunction market in the Middle East — and we are working on a US partner .”

America has the world’s highest number of ED sufferers by far, and Barder said Futura had “interest from a number of parties”. Signing a commercial deal there would be likely to trigger a share price surge.

“The announcement of that US partner will be crucial as it’s very early days for Eroxon,” said Seb Jantet, an analyst at house broker Liberum. “But there are early signs of success.”

In the UK, where Futura’s product first hit Boots’s shelves exclusively in April, almost £2 million worth of Eroxon was sold in the first eight weeks, the firm told capital market day attendees last month. Its launch partner said it had been one of its most successful over-the-counter launches.

Futura is anticipating sales of £3 million this year — stocking orders from the small markets of the UK and Belgium. “These don’t really show the scale of what the product could do,” Jantet added. But Futura has more than £4 million in cash and a strong balance sheet. There are no guarantees of a happy ending, but it’s a worthy punt. Buy.
Posted at 28/6/2023 13:53 by wheeze
One has to ask the obvious question as to why the odious LomBO1 keeps posting here with repetitive spam posts. After all he/she /it does not have any shares in FUM. Possibilities include:1. An aggrieved ex employee with an abiding hatred of the company2. Someone with genuine altruism trying their best to prevent small PIs from getting burned 3.someone in the pay of a large player who has a vested interest in keeping lots of new investors piling in with a resulting escalation in share price. After all if the share price remains low, it should be possible to take the company private with a lowball offer.I cannot think of any other reasonable explanations. I know which answer I would pick !
Futura Medical share price data is direct from the London Stock Exchange

Your Recent History

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |